Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]
Ann MedTan S, Li Y, Cao Y, Sun W, Hui W.
europepmc +1 more source
Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors. [PDF]
Neurooncol AdvHouse TO +13 more
europepmc +1 more source
XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]
Cell Commun SignalXu TT +8 more
europepmc +1 more source
Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration. [PDF]
Front ImmunolFeng X +5 more
europepmc +1 more source
Erratum: <i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]
Transl Lung Cancer ResEditorial Office.
europepmc +1 more source
Drug Discovery of Allosteric Molecular Glue Degraders (aMGDs): Expanding the Landscape of Targeted Protein Degradation. [PDF]
J Med ChemXue Y, Ali S, Chen H, Zhou J.
europepmc +1 more source
Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. [PDF]
CellsDi Marco MV +3 more
europepmc +1 more source
CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma. [PDF]
iScienceCao Y +10 more
europepmc +1 more source
<i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]
Transl Lung Cancer ResFalk M +4 more
europepmc +1 more source